Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raltegravir.

Jamie D Croxtall1, Katherine A Lyseng-Williamson, Caroline M Perry

  • 1Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|December 18, 2007
PubMed
Summary
This summary is machine-generated.

Raltegravir, an HIV-1 integrase inhibitor, significantly reduces viral load and increases CD4+ cell counts in patients with HIV-1. This new HIV therapy was well-tolerated in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.

Drugs·2020
Same author

Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer.

Drugs·2020
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2020
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same author

Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same author

Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.

Clinical drug investigation·2019
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Infectious Diseases
  • Virology
  • Pharmacology

Background:

  • HIV-1 integrase inhibitors represent a novel class of antiretroviral agents.
  • Raltegravir targets the strand transfer activity of HIV-1 integrase, a critical step in viral replication.
  • Understanding the efficacy and safety of raltegravir is crucial for HIV-1 management.

Purpose of the Study:

  • To evaluate the efficacy and safety of raltegravir in combination with optimized background therapy (OBT) in HIV-1 infected patients.
  • To assess the impact of raltegravir on viral load and CD4+ cell counts.
  • To determine the tolerability profile of raltegravir therapy.

Main Methods:

  • Two ongoing, randomized, double-blind, placebo-controlled, multicentre phase III trials were conducted.

Related Experiment Videos

  • Patients received either raltegravir plus OBT or placebo plus OBT.
  • Primary endpoint: proportion of patients achieving HIV-1 RNA loads <400 copies/mL at 24 weeks. Secondary endpoint: change in CD4+ cell counts.

    • Main Results:

    • Significantly greater proportions of patients achieved HIV-1 RNA loads <400 copies/mL and <50 copies/mL in the raltegravir plus OBT group compared to placebo plus OBT.
    • Mean CD4+ cell counts significantly increased from baseline in patients receiving raltegravir plus OBT.
    • Raltegravir therapy was generally well-tolerated, with similar incidences of mild to moderate adverse events between treatment arms.

    Conclusions:

    • Raltegravir, in combination with OBT, demonstrates significant efficacy in suppressing HIV-1 replication and improving immune status.
    • Raltegravir represents a safe and effective treatment option for HIV-1 infection.
    • Early results suggest raltegravir is a valuable addition to the antiretroviral therapy armamentarium.